Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Some mammals have a large larynx and thus a low-pitched voice, namely the hammer-headed bat (Hypsignathus monstrosus) where the larynx can take up the entirety of the thoracic cavity while pushing the lungs, heart, and trachea into the abdomen. Large vocal pads can also lower the pitch, as in the low-pitched roars of big cats. The production of infrasound is possible in some mammals such as the African elephant (Loxodonta spp.) and baleen whales. Small mammals with small larynxes have the ability to produce ultrasound, which can be detected by modifications to the middle ear and cochlea. Ultrasound is inaudible to birds and reptiles, which might have been important during the Mesozoic, when birds and reptiles were the dominant predators. This private channel is used by some rodents in, for example, mother-to-pup communication, and by bats when echolocating. Toothed whales also use echolocation, but, as opposed to the vocal membrane that extends upward from the vocal folds, they have a melon to manipulate sounds. Some mammals, namely the primates, have air sacs attached to the larynx, which may function to lower the resonances or increase the volume of sound. The vocal production system is controlled by the cranial nerve nuclei in the brain, and supplied by the recurrent laryngeal nerve and the superior laryngeal nerve, branches of the vagus nerve. The vocal tract is supplied by the hypoglossal nerve and facial nerves. Electrical stimulation of the periaqueductal gray (PEG) region of the mammalian midbrain elicit vocalizations.
Alcohol: It has been reported that combined use of alcohol and kava extract can have additive sedative effects. Kava has been shown to create additive cognitive impairments when taken with alcohol, compared to taking placebo and alcohol alone. Anxiolytics (CNS depressants such as benzodiazepines and barbiturates): Kava may have potential additive CNS depressant effects (such as sedation and anxiolytic effects) with benzodiazepines and barbiturates. Kava taken in combination with alprazolam can cause a semicomatose state in humans. Dopamine agonist such as levodopa: One of levodopa's chronic side effects in Parkinson's patients is the "on-off phenomenon" of motor fluctuations - periods of oscillations between "on", where the patient experiences symptomatic relief, and "off", where the therapeutic effect wears off early. When levodopa and kava are taken together, it has been shown that there is an increased frequency of this "on-off phenomenon".
Biden campaigned heavily for Democrats in the 2010 midterm elections, maintaining an attitude of optimism in the face of predictions of large-scale losses for the party. After big Republican gains in the elections and Emanuel's departure, Biden's past relationships with Republicans in Congress became more important. He led the successful administration effort to gain Senate approval for the New START treaty. In December 2010, Biden's advocacy for a middle ground, followed by his negotiations with Senate minority leader Mitch McConnell, were instrumental in producing the administration's compromise tax package that included a temporary extension of the Bush tax cuts. The package passed as the Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010. Obama delegated Biden to lead negotiations with Congress during the 2011 U.S. debt ceiling crisis. Biden's relationship with McConnell brought about the Budget Control Act of 2011 that solved the crisis. Some reports suggest that Biden opposed proceeding with the May 2011 U.S. mission to kill Osama bin Laden, lest failure adversely affect Obama's reelection prospects. In 2012, Biden made the case for Obama's reelection: "Osama bin Laden is dead and General Motors is alive." Obama named Biden to head the Gun Violence Task Force, created to address the causes of school shootings and consider possible gun control measures in the aftermath of the Sandy Hook Elementary School shooting, in December 2012.
Sources: en.wikipedia.org
== Current events and advocacy == The management of CEC has gained increasing attention in recent years due to their potential impact on public health and the environment. In response to these concerns, various governmental and international organizations have initiated efforts to address CEC through research, regulation, and public outreach. In January 2024, the White House Office of Science and Technology Policy announced a coordinated federal research initiative to address CEC in surface waters. The initiative aims to enhance understanding of the sources, occurrence, and effects of CEC, as well as to develop effective strategies for their removal and management. Furthermore, the Organization for Economic Co-operation and Development (OECD) has been actively involved in addressing CEC. The OECD Workshop on Managing Contaminants of Emerging Concern in Surface Waters brought together experts from various countries to discuss challenges and solutions related to CEC, emphasizing the importance of international collaboration in tackling this global issue. These recent developments underscore the growing recognition of the need for concerted efforts to address the challenges posed by CEC to protect public health and the environment. Advocacy efforts for the regulation of CEC are important to push for legislation and regulatory action. Environmental advocacy groups raise awareness about the potential risks associated with CEC and urge for the advancement of environmental protection policies.
Pulp degeneration Increasing age Orthodontic treatment Traumatic occlusion Dental caries Pulp stones usually consist of circular layers of mineralised tissues. These layers are made up of blood clots, dead cells and collagen fibres. Occasionally, pulp stones appear surrounded by odontoblast-like cells that contain tubules. Pulp stones can reach as high as 50% in surveyed samples. Pulp stones are estimated to typically range from 8–9%. Pulpal calcifications are more common in females and more frequent in maxillary teeth compared to mandibular teeth. The reason is uncertain. They are more common in molar teeth, especially first molars compared to second molars and premolars. A review suggested this was because the first molars are the first teeth to be located in the mandible (lower jaw) and have longer exposure to degenerative changes. They also have a larger blood supply. In general, pulp stones do not require treatment. Depending on the stones' size and location, they may interfere with endodontic treatment and should be removed.
4-Substituted-2,5-dimethoxyamphetamines (DOx) is a chemical class of substituted amphetamine derivatives featuring methoxy groups at the 2- and 5- positions of the phenyl ring, and a substituent such as alkyl or halogen at the 4- position of the phenyl ring. They are 4-substituted derivatives of 2,5-dimethoxyamphetamine (2,5-DMA, DOH) and are structurally related to the naturally occurring phenethylamine psychedelic mescaline. The most well-known DOx drugs are DOM, DOI, DOB, DOET, and DOC. DOI is widely used in scientific research. DOM has been used as a recreational drug, while DOET was an experimental pharmaceutical drug. Most compounds of this class are potent and long-lasting psychedelic drugs, and act as selective 5-HT2A, 5-HT2B, and 5-HT2C receptor agonists. A few bulkier derivatives such as DOAM have similarly high affinity for 5-HT2 receptors but have reduced efficacy and potency as psychedelics. DOI has been found to have extraordinarily potent anti-inflammatory effects. These properties are not shared by all other related drugs and appear to be mediated by functionally selective serotonin 5-HT2A receptor activation. The anti-inflammatory effects of DOI and related drugs may have medical applications.
The term "Han" not only refers to a specific ethnic collective, but also points to a shared ancestry, history, and cultural identity. The term "Huaxia" was used by the ancient Chinese philosopher Confucius's contemporaries during the Warring States period to elucidate the shared ethnicity of all Chinese; Chinese people called themselves "Hua people" (华人; 華人; Huárén). The Warring States period led to the emergence of the Zhou-era Chinese referring to themselves as being Huaxia (literally 'the beautiful grandeur'): under the Hua–Yi distinction, a "Hua" culture (often translated as 'civilized') was contrasted to that of peoples perceived as "Yi" (often translated as 'barbarian') living on the peripheries of the Zhou kingdoms. Overseas Chinese who possess non-Chinese citizenship are commonly referred as Huaren or Huazu (华族; 華族; Huázú). The two respective aforementioned terms are applied solely to those with a Han background that is semantically distinct from Zhongguo ren (中国人; 中國人) which has connotations and implications limited to being citizens and nationals of China, especially with regard to ethnic minorities in China. In English, the terms "Han Chinese", "ethnic Chinese", and "Chinese" people, are often conflated.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.